Company · CIK 0002093101 · SIC 2834 — Pharmaceutical Preparations · Nasdaq
Atrium Therapeutics, Inc. · RNA
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 18, 2026 FForm 4 → | Sep 22, 4:24 pm EDT | Husam YounisChief Scientific Officer | 11,216 | $8.95 | $100,383 | 41,441 | — | |
| Sep 18, 2026 FForm 4 → | Sep 22, 4:23 pm EDT | Steven George HughesChief Medical Officer | 21,459 | $8.95 | $192,058 | 51,638 | — | |
| Sep 18, 2026 FForm 4 → | Sep 22, 4:20 pm EDT | W. Michael FlanaganDirector | 22,812 | $8.95 | $204,167 | 31,974 | — | |
| Sep 18, 2026 FForm 4 → | Sep 22, 4:20 pm EDT | Sarah BoyceDirector | 126,418 | $8.95 | $1,131,441 | 138,668 | — | |
| Sep 18, 2026 FForm 4 → | Sep 22, 4:18 pm EDT | Stephanie KenneySee Remarks | 2,375 | $8.95 | $21,256 | 33,085 | — | |
| Sep 18, 2026 FForm 4 → | Sep 22, 4:17 pm EDT | Kathleen P. GallagherSee Remarks, Director | 11,632 | $8.95 | $104,106 | 119,729 | — | |
| Sep 18, 2026 FForm 4 → | Sep 22, 4:17 pm EDT | Brendan R. WinslowChief Financial Officer | 6,742 | $8.95 | $60,341 | 36,859 | — | |
| Sep 18, 2026 FForm 4 → | Sep 22, 4:15 pm EDT | Rocio Martin HoyosChief Strategy Officer | 8,320 | $8.95 | $74,464 | 38,340 | — |
Reported at this company — derivatives (options, RSUs, warrants)
No reported derivative activity in this period.